Evidence map›Paper›PMID 27047493›Full record

ReviewFrontiers in immunology2016

The Homophilic Domain - An Immunological Archetype.

Heinz Kohler, Jagadeesh Bayry, Srinivas V Kaveri

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Frontiers in immunology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.1field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 3 institutions in 2 countries.

Heinz KohlerDepartment of Microbiology Immunology, University of Kentucky , Lexington, KY , USA.
Jagadeesh BayryInstitut National de la Santé et de la Recherche Médicale Unité 1138, Paris, France; Centre de Recherche des Cordeliers, Equipe - Immunopathologie et immuno-intervention thérapeutique, Paris, France; Sorbonne Universités, UPMC Univ Paris 06, UMR S 1138, Paris, France; Université Paris Descartes, Sorbonne Paris Cité, UMR S 1138, Paris, France.
Srinivas V KaveriInstitut National de la Santé et de la Recherche Médicale Unité 1138, Paris, France; Centre de Recherche des Cordeliers, Equipe - Immunopathologie et immuno-intervention thérapeutique, Paris, France; Sorbonne Universités, UPMC Univ Paris 06, UMR S 1138, Paris, France; Université Paris Descartes, Sorbonne Paris Cité, UMR S 1138, Paris, France.
Délégation Paris 5 · FRUniversité Paris Cité · FRUniversity of Kentucky · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The homophilic potential emerges as an important biological principle to boost the potency of immunoglobulins. Since homophilic antibodies in human and mouse sera exist prior environmental exposure, they are part of the natural antibody repertoire. Nevertheless, hemophilic properties are also identified in induced antibody repertoire. The use of homophilicity of antibodies in the adaptive immunity signifies an archetypic antibody structure. The unique feature of homophilicity in the antibody repertoire also highlights an important mechanism to boost the antibody potency to protect against infection and atherosclerosis as well to treat cancer patients.

Indexed as

1F7homophilicidiotypeimmunoglobulinsinduced antibodiesnatural antibodiesT15

Identifiers

PMID27047493
PMCPMC4800165
OpenAlexW2323514330

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.